

CONSORT 2025 expanded checklist of detailed information to include when reporting a randomised trial

Section / Topic	No	CONSORT 2025 checklist item description	Detailed item description
Title and abstract			
Title and structured abstract	1a	NA	Use the word “randomised” in the title
	1b	Structured summary of the trial design, methods, results, and Conclusions have been included. Please find in the manuscript.	• Specific objectives • Trial design (e.g., parallel group, cluster) and framework (e.g., superiority, equivalence, non- inferiority, exploratory) • Methods: ○ Eligibility criteria for participants and settings where the trial was conducted ○ Intervention(s) and comparator(s) intended for each group ○ Primary outcome(s) ○ How participants were allocated to interventions (e.g., centralised computer-generated randomisation) ○ Who was blinded after assignment to interventions (e.g., participants, care providers, outcome assessors) • Results: ○ Number of participants randomised to each group ○ For the primary outcome, the number of participants analysed in each group ○ For the primary outcome, a result for each group and the estimated effect size and its precision ○ Important harms or unintended events for each group • Conclusions: ○ General interpretation of the results • Name of trial register and identification number • Sources of funding *Do not report information that does not appear in the body of the paper*
Open science			
Trial registration	2	www. ClinicalTrials. gov. NCT05164458. This study was registered on 12, 20, 2021.	• Name of registry • Trial registry identifying number • URL to registry record

			• Date of registration • Whether the trial results are already publicly posted to the trial registry, as a preprint (with URL citation) or published articles (with citations)
Protocol and statistical analysis plan	3	The data and materials that support the findings of this study are available from the corresponding author upon reasonable request.	• Where the protocol can be accessed with URL to its location (e.g., publication with DOI, repository such as Open Science Framework (OSF), trial registry, supplement to the trial report) • Where the full statistical analysis plan can be accessed with URL to its location (e.g., publication with DOI, repository such as Open Science Framework, trial registry, supplement to the trial report)
Data sharing	4	The data and materials that support the findings of this study are available from the corresponding author upon reasonable request.	• What data and materials are shared, for example: ○ De-identified participant data, data dictionary, analytical code used to process the data ○ Materials associated with the intervention (e.g., handbook or video for non-pharmacological interventions) • Where the data and materials are accessible (e.g., upon request, through a data sharing platform) • How the data and materials are shared (e.g., application process to access the data) • If no sharing is planned, this should be clearly stated with an explanation
Funding and conflicts of interest	5a	This study was funded by Innovent Biologics (Suzhou) Co. Ltd. This part has been included in the manuscript.	• Name of funder(s) • Type of funding: ○ Direct monetary support ○ Indirect support (free trial drugs, equipment, or services such as statistical analysis or use of medical writers) • Role of the funder(s) in the trial design, conduct, data analysis and reporting
	5b	Qian Wu, Yulong Zhang, and Hui Zhou reported being employees of Innovent Biologics (Suzhou) Co. Ltd. Other authors declare that they have no competing interests. This part has been included in the manuscript.	• Conflicts of interests of the trial manuscript authors, including: ○ Financial: salary support or grants; ownership of stock or options; honoraria (e.g., for advice, authorship, or public speaking); paid consultancy or service on advisory boards; and holders of patents or patents pending ○ Non-financial: academic commitments; personal or professional relationships; other affiliations with special interests or advocacy positions • Any procedures to reduce the influence of conflicts of interest on the trial's design, conduct, analysis, or reporting

			• If no conflicts of interest, this should be clearly stated
Introduction			
Background and rationale	6	This part has been included in the manuscript.	• Importance of the research question • Why a new trial is needed in the context of available evidence ○ Explanation of how the intervention might work ○ Justification of the choice of comparator ○ Evidence of the benefits and harms of the intervention ○ Reference to systematic review(s) of relevant trials where available
Objectives	7	This part has been included in the manuscript.	• Trial objective(s) related to benefits and harms including: ○ Participants ○ Intervention(s) ○ Comparator(s) ○ Primary outcome(s) ○ Timepoint of primary outcome • If the trial was designed using the estimands framework, the objectives should be defined in terms of this framework
Methods			
Patient and public involvement	8	This part has been included in the manuscript.	• How patients and the public were involved at different trial stages (e.g., design, conduct, reporting) • Who was involved (e.g., patients, carers, or members of the public) • If no patient or public involvement, this should be stated
Trial design	9	This part has been included in the manuscript.	• Type of trial design (e.g., parallel group) • Conceptual framework (e.g., superiority, non-inferiority, or equivalence) • Unit of randomisation (e.g., individual participant) • Allocation ratio (e.g., 1:1)
Changes to trial protocol	10	NA	• Any changes to the original protocol after the trial commenced with timing and reasons, e.g., in randomisation ratio, eligibility criteria, interventions, outcomes (method of assessment, timepoint, changes of outcomes), target sample size, number of trial groups, duration of follow-up, analysis methods, trial conduct (such as dropping a site with poor data quality), any other important changes • Any outcomes that were not prespecified

			Any analyses that were not prespecified
Trial setting	11	This part has been included in the manuscript.	- Location(s) where the trial was carried out (e.g., country, city) - Setting of participant recruitment (e.g., primary or tertiary care; outpatient community or hospital clinic, inpatient unit) - Number of sites
Eligibility criteria	12a	This part has been included in the manuscript.	- All inclusion and exclusion criteria - Methods of recruitment (e.g., referral or self-selection; advertisements)
	12b	NA	If applicable: - Eligibility criteria for sites, for example the sites volume for the procedure - Eligibility criteria for individuals delivering the interventions (e.g., surgeons, physiotherapists), such as professional qualifications, years in practice, skills, validation of specific training before trial initiation
Intervention and comparator	13	This part has been included in the manuscript.	- Details of each intervention and comparator to allow replication including for example: - Components of the intervention and comparator - How they were administered - When and for how long they were administered - Any procedure for tailoring the intervention/comparator to individual participants - Any physical or informational materials used as part of the intervention/comparator (e.g., instruction manual) and where the materials can be accessed - Where appropriate, relevant concomitant care and interventions that are allowed (e.g., rescue interventions) or prohibited during the trial - Where appropriate, criteria used to guide modifications to the trial intervention/comparator (e.g., drug dose change in response to harms, participant request, or improving/worsening disease) and discontinuations of the trial intervention/comparator - When the comparator group is “usual care”: - Description of usual care - Whether the intervention group(s) also received usual care - When and how fidelity of care providers and adherence of participants to the intervention/comparator protocols were assessed, if applicable - Any strategies for improving fidelity of care providers and adherence of participants to the intervention/comparator protocols

			• Where appropriate, prespecified definition for classifying participants as being treated as planned or not
Outcomes	14	This part has been included in the manuscript.	• Which outcomes are primary and secondary as prespecified in the protocol • Rationale for the choice of trial outcomes and whether they are part of a core outcome set • For each outcome: ○ Specific variable measured (e.g., Beck Depression Inventory score) with definition where relevant (e.g., major bleeding was defined as fatal bleeding or symptomatic bleeding in a critical area or organ; all-cause mortality as per hospital database) ○ Analysis metric for each participant (e.g., change from baseline, end value, time-to-event) ○ Method of aggregation for each trial group (e.g., median, proportion with score > 2) ○ Timepoint of interest for analysis (e.g., 3 months) ○ Who assessed outcomes (patient, doctor, nurse, caregiver, other)
Harms	15	This part has been included in the manuscript.	• For each systematically assessed harm (active/targeted surveillance): ○ Definition and measurement (e.g., name of a validated questionnaire) ○ Where appropriate, the metrics, method of aggregation and time point of interest for analysis (see item 14) ○ Procedures for harms assessment, including: . Who did the assessment, and whether they were blinded to the allocated trial group . Assessment time points and the overall time period for recording • harms For each non-systematically assessed harm (passive surveillance): ○ How data were collected ○ Assessment time points and overall time period for recording harms ○ Process for coding each harm and grading its severity, including: . Who did the coding and severity grading, and whether they were blinded to the allocated trial group . Which coding and severity grading systems were used, if any • For grouping of harms by seriousness, severity, body system, withdrawals (due to harms), and causality: ○ Definitions of grouping categories

			○ Who did the grouping, and whether they were blinded to the allocated trial group
Sample size	16a	This part has been included in the manuscript.	• Primary outcome on which the calculations are based • Outcome values (e.g., proportion) assumed for each group, with rationale or supporting references • Target difference in outcome values between trial groups (including common standard deviation for continuous outcomes), with rationale • Statistical significance level or α (type I) error • Statistical power or β (type II) error • Any adjustments to account for e.g., missing data or non-adherence • Target sample size per trial group • Any software used for sample size calculation
	16b	NA	Interim analyses: • Whether interim analyses were conducted • Whether interim analyses were pre-planned • When they were conducted (timing and indications), and by whom • Statistical methods • Who had access to interim results, and whether they were blinded • Whether an independent Data Monitoring Committee was involved Stopping guidelines: • Any criteria (statistical or non-statistical) used to inform decisions about early stopping or other adaptations (e.g., sample size re-estimation) • Who made the decision to continue, stop, or modify the trial
Randomisation:			
Sequence generation	17a	NA	• Who generated the allocation sequence • Method of sequence generation (e.g., computerised random number generator) • Any software used for random sequence generation
	17b	NA	• Type of randomisation: simple versus restricted (e.g., blocked); fixed versus adaptive (e.g., minimisation, urn); and where relevant, the reasons for such choices • Methods used for restriction: ○ Block randomisation: ▪ How blocks were generated (e.g., permuted block design with a computer random number generator)

			. Block size(s) . Whether block size(s) was fixed or randomly varied . Whether trialists were or became aware of block size(s) ○ Stratification: . Factors of stratification (e.g., site, sex, disease stage) ○ Minimisation: . Factors incorporated . Whether a random element was used, and details
Allocation concealment mechanism	18	NA	• How the individuals enrolling participants were made unaware of the next trial group assignment in the random sequence (not to be confused with blinding)
Implementation	19	NA	• Who had access to the random allocation sequence • Who enrolled participants • Who assigned participants to interventions • Whether personnel enrolling and assigning participants had access to the random allocation sequence. • When individuals involved in sequence generation and allocation concealment are the same individuals involved in the implementation of assignment: ○ How and where the allocation list was stored ○ Any mechanisms to prevent those enrolling and assigning participants from accessing the list (e.g., allocation sequence was locked in a secure location)
Blinding	20a	NA	Who was blinded to trial group assignments: • Trial participants • Care providers (i.e., those administering the intervention) • Data collectors (those collecting data on the trial outcomes) • Outcome assessors (i.e., those who determine if a participant experienced the outcome of interest), e.g., the participant for patient reported outcomes, the care provider, an independent researcher • Data analysts performing the statistical analysis

	20b	NA	• Mechanism used to establish blinding (e.g., identical placebo, double-dummy) • Any similarities or differences of the characteristics (e.g., appearance, taste) of the interventions being compared • Any procedures intended to maintain blinding and reduce risk of unblinding, when appropriate • Any procedures intended to evaluate blinding procedures (e.g., pre-trial testing of blinding procedures) • Any known compromises in blinding (e.g., unblinding of any participants or caregivers during the trial) • If done, any emergency unblinding with reasons and the procedure used
Statistical methods	21a	NA	• Statistical methods for each analysis: ○ Main analysis methods for statistical comparison ○ Any deviation from the statistical analysis plan ○ Distinction between prespecified and post-hoc analyses ○ Effect measure (e.g., absolute risk) with confidence intervals ○ Statistical significance level • For Bayesian analysis: choices of priors, computational choices, details of any modelling, effect measure with credible intervals • For adjusted analyses (if applicable): ○ Rationale for adjusted analyses ○ Whether adjusted analyses were pre-specified or post hoc ○ Choice of covariates adjusted for ○ Statistical methods (including how continuous covariates were handled) • Methods to account for multiplicity, if applicable • Software used for analyses
	21b	NA	• Who was included in the primary and other analyses (e.g., all randomised participants with either observed or imputed outcome data): ○ Any exclusions due to missing data or other reasons • Trial group in which participants were analysed (e.g., as-randomised)

	21c	NA	For each analysis: • Assumption about the missing data mechanism (e.g., missing at random) with justification • How missing data were handled (e.g., multiple imputation, model-based approaches), with justification • Whether sensitivity analyses were conducted
	21d	NA	• Whether additional analyses were pre-specified or post hoc (i.e., suggested by the data) • Whether all additional analyses conducted are reported For sensitivity analyses: • Rationale • Statistical methods For subgroup analyses: • Baseline variables explored • Rationale • Statistical methods (e.g., test of interaction)
Results			
Participant flow, including flow diagram	22a	Please find these contents in Figure 1.	In a flow diagram, the number of participants: • Evaluated for potential enrolment, if recorded • Excluded before randomisation with reasons: • Not meeting the inclusion criteria • Declined to participate • Other reasons • Randomly assigned to each group • Who received intervention as allocated, by trial group • Who completed intervention as allocated, by trial group • Who completed follow-up as planned, by trial group • Included in the main analysis for the primary outcome, by trial group Where appropriate (e.g., nonpharmacologic interventions): • the number of care providers or centres performing the intervention in each group • the number of participants treated by each care provider or in each centre

	22b	NA	In a flow diagram, the number of participants: • Lost to follow up, by trial group • Excluded from main analysis for the primary outcome, by trial group with reasons The wording “protocol deviation” is not sufficiently explicit and exact reasons should be reported
Recruitment	23a	First enrollment: 10/11/2023; Last enrollment: 03/29/2024 The end of follow-up (cut-off date): 09/13/2024 Median follow-up time (months): 10 months, range: 2.0-18.2 months.	• Start and completion date of participant recruitment • Date when follow up ended • Duration of follow-up (e.g., median, interquartile range, minimum, maximum)
	23b	If relevant, why the trial ended or was stopped.	If relevant, • Reason for stopping the trial before completion as planned (e.g., result of an interim analysis, lack of funding, difficulty in recruiting patients) • Who made the decision to stop • Role of funder in decision to stop
Intervention and comparator delivery	24a	This part has been included in the manuscript.	• Who actually delivered the intervention/comparator (number and expertise) • How the intervention/comparator was actually administered • What intervention/comparator was actually administered • Participants’ adherence to the intervention/ comparator • Whether the intervention/comparator was delivered as intended (i.e., care provider’s fidelity), where appropriate
	24b	Concomitant care received during the trial for each group were collected.	In each trial group: • Number and percentage of participants receiving the different relevant concomitant interventions (i.e., interventions that could have affected the outcome) • Where relevant, the cumulative or average for each concomitant intervention taken over the trial period
Baseline data	25	Please find this information in Table 1.	Baseline characteristics for participants in each group in a table detailing: • For continuous variables: ○ Mean with standard deviation or median with percentiles (e.g., 25th, 75th), where appropriate • For binary and categorical variables: ○ Numbers and percentages

Numbers analysed,	26	This part has been included in the manuscript.	For all planned primary and secondary outcomes, in each group: • The number of participants included in analysis • The number of participants with available data at the outcome time point
-------------------	----	--	--

outcomes and estimation			• Reasons for missing data • For continuous outcomes: ○ Summary of the outcome in each group (e.g., mean with standard deviation) ○ Effect size (e.g., difference in means) and its precision (e.g., 95% confidence interval) • For binary or time-to-event outcomes: ○ Summary of the outcome in each group (e.g., number of participants with the outcome event and denominator) ○ Both absolute (e.g., risk difference, difference in median survival time, difference of restricted mean survival time) and relative effect size (e.g., risk ratio, odds ratio, hazard ratio, ratio of restricted mean survival time) and its precision (e.g., 95% confidence interval)
Harms	27	This part has been included in the manuscript.	For each group preferably in a table with the number of participants at risk: • Number of deaths • Number of participants withdrawn due to harms For the systematically assessed harms, non-systematically assessed harms, and serious harms in each group preferably in a table with the number of participants at risk: • Number of participants with at least one harm event • Number of events, if appropriate • If no adverse events were identified, this should be stated. • Where appropriate ○ The estimated effect size and its precision (95% confidence interval) ○ For binary outcomes/time-to-event outcomes, both absolute and relative effects
Ancillary analyses	28	NA	• Results for all other analyses performed • Describe which were pre-specified and which were post-hoc analyses
Discussion			
Interpretation	29	This part has been included in the manuscript.	• Brief summary of the trial results, balancing both benefits and harms of the intervention(s) • How the trial results relate to existing evidence (e.g. systematic review) • Avoid overinterpretation ((spin9)

Limitations	30	This part has been included in the manuscript.	• Any methodological limitations and, if relevant, any methods used to minimise or mitigate them • Any imprecision in the results • Generalisability of the results
-------------	----	--	---

Citation: Hopewell S, Chan AW, Collins GS, Hróbjartsson A, Moher D, Schulz KF, et al. CONSORT 2025 Statement: updated guideline for reporting randomised trials. BMJ. 2025; 388:e081123.<https://dx.doi.org/10.1136/bmj-2024-081123>

© 2025 Hopewell et al. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<https://creativecommons.org/licenses/by/4.0/>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

*We strongly recommend reading this statement in conjunction with the CONSORT 2025 Explanation and Elaboration for important clarifications on all the items. We also recommend reading relevant CONSORT extensions. See www.consort-spirit.org.